A reduction in LDL-C is associated with improvements in CV outcomes in patients with ASCVD.¹ As such, multiple guidelines recommend LDL-C targets of <55mg/dL and <70mg/dL based on baseline risks.¹ However, many patients fail their LDL-C goals due to clinical inertia, medication nonadherence, side effects, and/or poor healthcare access.¹ Inclisiran is a first-in-class siRNA that inhibits hepatic PCSK9 production and increases LDL receptor expression and LDL-C clearance.¹ In clinical studies, twice-yearly administration of inclisiran has been shown to achieve a 50% reduction in LDL-C.¹

Inclisiran is a first-in-class small interfering ribonucleic acid (siRNA) targeting hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) and lowering low-density lipoprotein-cholesterol (LDL-C).1 Administered subcutaneously at a dose of 284mg initially, at 3 months, and every 6 months there

Atherosclerotic cardiovascular disease (ASCVD) continuesto be a leading cause of morbidity and mortality worldwide,with over 17.9 million people dying from cardiovascular (CV)diseases annually.1,2 Given the fact that the recurrent riskis high among patients with established ASCVD, secondarypreventio

In the European Society of Cardiology (ESC) Congress 2022, Dr. Duk-Woo Park from the University of Ulsan College of Medicine, Seoul, Korea, presented the results of his group’s investigation into the effectiveness of routine functional testing as a follow-up strategy after percutaneous coronary inte

Mixed data have been observed on the role of statins in the preventative setting of cardiovascular disease (CVD).¹ However, Dr. Raffaele Bugiardini, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy and his colleagues conducted a recent study published in the Journal of the American College of Cardiology, which demonstrated evidence that receiving statin therapy before initial acute coronary syndrome (ACS) could reduce acute heart failure (AHF) and improve patient survival rates.²

High levels of low-density lipoprotein cholesterol (LDL-C) is a potent risk factor for atherosclerotic cardiovascular disease that contributes to approximately 45% of all heart attacks.¹ While statins remain the cornerstone therapy for dyslipidemia and are generally well-tolerated, 25-30% of patients would show some forms of statin intolerance resulting in treatment discontinuation.² As lipid-lowering treatment discontinuation may increase the risk of cardiovascular events, it is clinically important to make a correct diagnosis of statin intolerance to prevent the worsening of cardiovascular outcomes.³ In a recent interview with Omnihealth Practice, Dr. Yuan Gao, Specialist in Neurology, Queen Mary Hospital, shared the critical components of assessing statin intolerance and the need to switch to a non-statin alternative such as proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) regimen if aggressive lipid-lowering treatment is required.

The 2017 Hypertension Clinical Practice Guideline issued by the American College of Cardiology/American Heart Association (ACC/AHA) Task Force outlined the general blood pressure (BP) management approach to adults with stage 1 hypertension and a 10-year risk for atherosclerotic cardiovascular diseas

Familial hypercholesterolemia (FH) is a common codominant monogenic dyslipidemia that can result in the lifelong and prominent elevation of plasma low-density lipoprotein cholesterol (LDL-C).^1,2 Whereas homozygous FH is rare with an estimated frequency of 1 in 160,000-320,000 individuals, heterozygo